EGFR and non-small cell lung carcinoma: For somatic EGFR mutations, classical exon 19 deletion and L858R represent the majority of EGFR mutations in NSCLC, and are positive prognostics towards specific EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib24,25.